focus -WSS

focus

author：hotspot 2025-08-28 08:40:50 - browse：4194

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： More regulation could be coming for drug ads

WSS

Families look for replacement for GSK asthma drug Flovent

Ancient Greek ideas underpin modern concepts of pregnancy

Why Talkspace is targeting Medicare, a tricky market

Lack of health data on LGBTQ+ people has serious consequences

Biden praises World Series champion Astros for impact off the field during White House celebration

Longer MASH drug regimen improved liver, Akero study finds

explore

focus

leisure time

What does generative AI mean for health care? We asked experts

In venture capital firm's success, lessons for turning crisis into profit

How to save PrEP access — and even expand it

Judge rejects Trump's counterclaim against E. Jean Carroll

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Medicare proposal to cover medical devices draws a mixed reaction

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Medicare details structure of new drug price negotiation program

First over

hotspot

Streamlined flu vaccines recommended by FDA advisory panel

First over

Germany receives 178 compensation applications from gay servicepeople over discrimination

$1 billion proposal to grow Boston, Massachusetts biotech

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

Ohioans vote in high

focus

entertainment

leisure time

knowledge